David Quigley, PhD

Title(s)Assistant Professor, Urology
SchoolSchool of Medicine
Address1450 Third Street, #001
San Francisco CA 94158
Phone415-710-7311
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Carleton College, Northfield MN USABA06/1998Computer Science
    Columbia University, New York NY USAMA06/2006Biomedical Informatics
    Oslo University, Oslo, NorwayPhD10/2014Genetics
    Collapse Awards and Honors
    8th annual PacRim Meeting2024  - 2024Rob Sutherland Award for Early or Mid-career Investigators
    UCSF2024  - 2024Outstanding Faculty Mentorship Award
    Prostate Cancer Foundation2017  - 2020Young Investigator Award

    Collapse Overview 
    Collapse Overview
    The Quigley Lab studies tumor genomes to understand how urological cancers develop and respond to therapy. Our lab is part of the Department of Urology and the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.

    Our lab studies tumor biopsies donated by cancer patients using molecular assays and computational methods for genome analysis. Our goal is to reconstruct how the tumor formed and changed by interrogating the tumor’s genome (DNA mutations and structural variation), epigenome (DNA methylation and shape), and transcriptome (gene activity levels). With this information, we can understand the biology of lethal cancer, develop new biomarkers to select which patients will respond to therapy, and understand how therapy resistance develops.

    Collapse Research 
    Collapse Research Activities and Funding
    Discovering transcriptional drivers of therapy-resistant metastatic prostate cancer
    DOD PC230564May 1, 2024 - Apr 30, 2027
    Role: PI
    Description: The goal of this study is to understand what drives treatment-resistant advanced prostate cancer by developing and applying novel machine learning approaches to analysis of epigenomic data.
    Advancing the Drug Development Process in Metastatic Prostate Cancer through Machine Learning
    Prostate Cancer Foundation 22CHAS02Sep 6, 2022 - Sep 5, 2024
    Role: co-PI

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Racial Variation in the Advanced Prostate Cancer Genome. International Journal of Radiation Oncology • Biology • Physics. 2024 Oct 1; 120(2):e519. Feng FE, Vo-Phamhi VJ, Foye FA, Vinson VJ, Hong HJ, Freedland FS, Alumkal AJ, Beltran BH, Morrissey MC, Nelson NP, Chinnaiyan CA, Sawyers SC, Aggarwal AR, Small SE, Quigley QD, Sjostrom SM, Zhao ZS, Chen CW. .
      View in: Publisher Site   Mentions:
    2. Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Sep 25. Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan H, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. PMID: 39321214.
      View in: PubMed   Mentions:    Fields:    
    3. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. Cancer Res. 2024 Sep 16; 84(18):3086-3100. Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, Weinstein AS, Sjöström M, Zhu X, Moreno-Rodriguez T, Li H, SU2C/PCF West Coast Prostate Cancer Dream Team, Alumkal JJ, Aggarwal R, Small EJ, Lupien M, Quigley DA, Feng FY. PMID: 38990734.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    4. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J Clin Invest. 2024 Aug 13; 134(19). Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, Sjöström M, Shrestha R, Kneppers J, Severson T, Zhang M, Lundberg A, Moreno Rodriguez T, Weinstein AS, Foye A, Mehra N, Aggarwal RR, Bergman AM, Small EJ, Lack NA, Zwart W, Quigley DA, van der Heijden MS, Feng FY. PMID: 39352383.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nat Genet. 2024 Aug; 56(8):1689-1700. Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sjöström M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, West Coast Dream Team Consortium, Lynch M, Dehm SM, Lang JM, Alumkal JJ, He HH, Wyatt AW, Aggarwal R, Zwart W, Small EJ, Quigley DA, Lupien M, Feng FY. PMID: 39020220; PMCID: PMC11319208.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    7. Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression. Nat Cell Biol. 2024 Jul; 26(7):1176-1186. Zhang M, Sjöström M, Cui X, Foye A, Farh K, Shrestha R, Lundberg A, Dang HX, Li H, Febbo PG, Aggarwal R, Alumkal JJ, Small EJ, SU2C/PCF West Coast Prostate Cancer Dream Team, Maher CA, Feng FY, Quigley DA. PMID: 38871824.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. A prostate cancer gastrointestinal transcriptional phenotype may be associated with diminished response to AR-targeted therapy. bioRxiv. 2024 Jun 03. Subramanian A, Zhang M, Sharifi M, Moreno-Rodriguez T, Feng E, Rydzewski NR, Shrestha R, Zhu X, Zhao SG, Aggarwal R, Small EJ, Ding CC, Quigley DA, Sjöström M. PMID: 38895460; PMCID: PMC11185575.
      View in: PubMed   Mentions:
    9. Development of a machine learning model to predict overall survival results from randomized clinical trials of patients with metastatic prostate cancer. Journal of Clinical Oncology. 2024 Jun 1; 42(16_suppl):5065-5065. Sabbagh SA, Quigley QD, Lillis LN, Zhang ZL, Friesner FI, Bailey BA, Aggarwal AR, Chappidi CM, Singhal SH, Zhang ZK, Greshock GJ, Li LJ, Yu YM, Small SE, Hong HJ. .
      View in: Publisher Site   Mentions:
    10. Stem-cell states converge in multistage cutaneous squamous cell carcinoma development. Science. 2024 May 31; 384(6699):eadi7453. Taylor MA, Kandyba E, Halliwill K, Delrosario R, Khoroshkin M, Goodarzi H, Quigley D, Li YR, Wu D, Bollam SR, Mirzoeva OK, Akhurst RJ, Balmain A. PMID: 38815020.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    11. Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer. Cancer Research. 2024 Apr 5; 84(7_Supplement):lb196-lb196. Shrestha SR, Chesner CL, Zhang ZM, Zhou ZS, Foye FA, Lundberg LA, Weinstein WA, Sjöström SM, Zhu ZX, Moreno-Rodriguez MT, Li LH, Alumkal AJ, Aggarwal AR, Small SE, Lupien LM, Quigley QD, Feng FF. .
      View in: Publisher Site   Mentions:
    12. Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer. NPJ Genom Med. 2024 Feb 23; 9(1):14. Saha D, Dang HX, Zhang M, Quigley DA, Feng FY, Maher CA. PMID: 38396008; PMCID: PMC10891057.
      View in: PubMed   Mentions:
    13. Somatostatin receptor 1 ( SSTR1 ) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):180-180. Zhu ZX, Vis VD, Sjöström SM, Shrestha SR, Kneppers KJ, Severson ST, Zhu ZY, Li LH, Farsh FT, Zhang ZM, Lundberg LA, Moreno Rodriguez MT, Foye FA, Bergman BA, Zwart ZW, Quigley QD, Aggarwal AR, Small SE, Van Der Heijden VM, Feng FF. .
      View in: Publisher Site   Mentions:
    14. Advancing the drug development process in metastatic prostate cancer through machine learning. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):192-192. Quigley QD, Hong HJ, Lillis LN, Sabbagh SA, Friesner FI, Bailey BA, Aggarwal AR, Zhang ZL, Chappidi CM, Singhal SH, Greshock GJ, Zhang ZK, Yu YM, Small SE. .
      View in: Publisher Site   Mentions:
    15. Association of a prostate cancer gastrointestinal transcriptional phenotype as found in clinical mCRPC samples with response to AR-targeted therapy. Journal of Clinical Oncology. 2024 Feb 1; 42(4_suppl):203-203. Subramanian SA, Zhang ZM, Sharifi SM, Moreno Rodriguez MT, Feng FE, Rydzewski RN, Shrestha SR, Zhu ZX, Zhao ZS, Aggarwal AR, Small SE, Ding DC, Quigley QD, Sjöström SM. .
      View in: Publisher Site   Mentions:
    16. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    17. AARDVARK: an automated reversion detector for variants affecting resistance kinetics. Bioinformatics. 2023 08 01; 39(8). Moreno T, Magana J, Quigley DA. PMID: 37584701; PMCID: PMC10457659.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2024 Apr; 7(2):222-230. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. PMID: 37474400.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    19. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023 09; 34(9):813-825. Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. PMID: 37330052; PMCID: PMC10527168.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Abstract PR003: Convergent evolution in DNA repair-deficient mCRPC in response to targeted therapy. Cancer Research. 2023 Jun 2; 83(11_Supplement):pr003-pr003. Moreno MT, Zhang ZM, Lundberg LA, Shrestha SR, Sjöström SM, Pasam PA, Foye FA, Trigos TA, Feng FF, Sandhu SS, Quigley QD. .
      View in: Publisher Site   Mentions:
    21. Abstract A029: Whole genome and transcriptome analysis of paired metastatic biopsies identified resistance mechanisms in castration-resistant prostate cancer. Cancer Research. 2023 Jun 2; 83(11_Supplement):a029-a029. Zhu ZX, Vis VD, Sjöström SM, Shrestha SR, Kneppers KJ, Severson ST, Zhu ZY, Zhang ZM, Lundberg LA, Rodriguez RT, Weinstein WA, Li LH, Foye FA, Aggarwal AR, Bergman BA, Small SE, Zwart ZW, Quigley QD, van der Heijden vM, Feng FF. .
      View in: Publisher Site   Mentions:
    22. Abstract A062: Alternative promoter usage is linked to transcriptional and epigenetic alterations during prostate cancer progression. Cancer Research. 2023 Jun 2; 83(11_Supplement):a062-a062. Zhang ZM, Sjöström SM, Shrestha SR, Lundberg LA, Moreno-Rodriguez MT, Foye FA, Dang DH, Alumkal AJ, Aggarwal AR, Small SE, Maher MC, Feng FF, Quigley QD. .
      View in: Publisher Site   Mentions:
    23. Abstract B041: AR suppresses MHC Class I expression and T-cell response in prostate cancer. Cancer Research. 2023 Jun 2; 83(11_Supplement):b041-b041. Chesner CL, Graff GJ, Polesso PF, Smith SA, Lundberg LA, Sjoestroem SM, Xia XZ, Linder LS, Bergman BA, Ashworth AA, Quigley QD, Zwart ZW, Gilbert GL, Moran MA, Feng FF. .
      View in: Publisher Site   Mentions:
    24. Abstract B031: Investigation of the ubiquitin ligase RNF31 as a mediator of immune evasion in advanced prostate cancer. Cancer Research. 2023 Jun 2; 83(11_Supplement):b031-b031. Liu LT, Li LH, Hua HT, Shin SH, Shenoy ST, Sjoestroem SM, Lundberg LA, Gilbert GL, Quigley QD, Ashworth AA, Lanier LL, Feng FF. .
      View in: Publisher Site   Mentions:
    25. Gene networks reveal stem-cell state convergence during preneoplasia and progression to malignancy in multistage skin carcinogenesis. bioRxiv. 2023 May 10. Taylor MA, Kandyba E, Halliwill K, Delrosario R, Koroshkin M, Goodarzi H, Quigley D, Li YR, Wu D, Bollam S, Mirzoeva O, Akhurst RJ, Balmain A. PMID: 37215032; PMCID: PMC10197547.
      View in: PubMed   Mentions:
    26. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023 04 10; 8(7). Sayar E, Patel RA, Coleman IM, Roudier MP, Zhang A, Mustafi P, Low JY, Hanratty B, Ang LS, Bhatia V, Adil M, Bakbak H, Quigley DA, Schweizer MT, Hawley JE, Kollath L, True LD, Feng FY, Bander NH, Corey E, Lee JK, Morrissey C, Gulati R, Nelson PS, Haffner MC. PMID: 36821396; PMCID: PMC10132157.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    27. Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 12 15; 28(24):5396-5404. Feng E, Rydzewski NR, Zhang M, Lundberg A, Bootsma M, Helzer KT, Lang JM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG. PMID: 36260524; PMCID: PMC9890931.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961. O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. PMID: 36273492; PMCID: PMC9633439.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    29. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    30. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    31. Why ARNT Prostate Tumors Responding to Enzalutamide? Cancer Discov. 2022 09 02; 12(9):2017-2019. Zhang M, Moreno-Rodriguez T, Quigley DA. PMID: 36052502.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 08; 608(7921):199-208. Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, SU2C/PCF West Coast Prostate Cancer Dream Team, Quigley DA, Feng FY, Chi KN, Wyatt AW. PMID: 35859180.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    33. Abstract 3625: Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing. Cancer Research. 2022 Jun 15; 82(12_Supplement):3625-3625. Herberts HC, Annala AM, Sipola SJ, Ng NS, Chen CX, Nurminen NA, Korhonen KO, Munzur MA, Beja BK, Schönlau SE, Bernales BC, Ritch RE, Bacon BJ, Lack LN, Nykter NM, Aggarwal AR, Small SE, Gleave GM, Quigley QD, Feng FF, Chi CK, Wyatt WA. .
      View in: Publisher Site   Mentions:
    34. Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer. Clin Epigenetics. 2022 05 04; 14(1):60. Severson T, Qiu X, Alshalalfa M, Sjöström M, Quigley D, Bergman A, Long H, Feng F, Freedman ML, Zwart W, Pomerantz MM. PMID: 35509021; PMCID: PMC9069737.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    35. Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022 Feb 20; 40(6_suppl):167-167. de Kouchkovsky dI, Zhang ZL, Huang HJ, Trepka TK, Chou CJ, Foye FA, Shui SD, Wong WC, Friedl FV, Weinstein WA, Hope HT, Quigley QD, Stuart SJ, Beer BT, Reiter RR, Gleave GM, Evans EC, Feng FF, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    36. Abstract PD15-08: Window of opportunity trial of neoadjuvant olaparib and durvalumab for triple negative or low ER-positive breast cancer. Cancer Research. 2022 Feb 15; 82(4_Supplement):pd15-08-pd15-08. Im IS, Lee LK, Min MA, Lee LD, Kim KT, Ryu RH, Koh KJ, Cheon CG, Shin SY, Kim KY, Moon MH, Han HW, Lee LH, Diolaiti DM, Quigley QD, Ashworth AA, Cho CN. .
      View in: Publisher Site   Mentions:
    37. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov 01; 7(11):1644-1652. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. PMID: 34554200; PMCID: PMC8461554.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    38. Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures. NPJ Genom Med. 2021 Sep 21; 6(1):76. Rydzewski NR, Peterson E, Lang JM, Yu M, Laura Chang S, Sjöström M, Bakhtiar H, Song G, Helzer KT, Bootsma ML, Chen WS, Shrestha RM, Zhang M, Quigley DA, Aggarwal R, Small EJ, Wahl DR, Feng FY, Zhao SG. PMID: 34548481; PMCID: PMC8455625.
      View in: PubMed   Mentions: 6  
    39. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat Commun. 2021 07 29; 12(1):4601. Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA. PMID: 34326322; PMCID: PMC8322386.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    40. CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. Nat Commun. 2021 03 19; 12(1):1781. Ahmed M, Soares F, Xia JH, Yang Y, Li J, Guo H, Su P, Tian Y, Lee HJ, Wang M, Akhtar N, Houlahan KE, Bosch A, Zhou S, Mazrooei P, Hua JT, Chen S, Petricca J, Zeng Y, Davies A, Fraser M, Quigley DA, Feng FY, Boutros PC, Lupien M, Zoubeidi A, Wang L, Walsh MJ, Wang T, Ren S, Wei GH, He HH. PMID: 33741908; PMCID: PMC7979745.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    41. 5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):148-148. Sjöström SM, Zhao ZS, Small SE, Ning NY, Maurice-Dror MC, Foye FA, Hua HJ, Li LH, Beer BT, Evans EC, Rettig RM, Chi CK, Alumkal AJ, Aggarwal AR, Ashworth AA, Levy LS, He HH, Wyatt WA, Quigley QD, Feng FF. .
      View in: Publisher Site   Mentions:
    42. Genomic characterization of treatment-associated small cell neuroendocrine carcinoma of the prostate. Journal of Translational Genetics and Genomics. 2021 Jan 1; 5(3):265-277. de Kouchkovsky dI, Quigley QD, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    43. One of These Things is Not Like the Others: Targeting ATM-mutant Prostate Cancer. Eur Urol. 2021 02; 79(2):212-213. Quigley DA. PMID: 33257032.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression. Sci Rep. 2020 09 28; 10(1):15890. Eteleeb AM, Quigley DA, Zhao SG, Pham D, Yang R, Dehm SM, Luo J, Feng FY, Dang HX, Maher CA. PMID: 32985524; PMCID: PMC7522247.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    45. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    46. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    47. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCells
    48. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 12; 38(12):931.e9-931.e16. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    49. The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):5507-5507. Small SE, Zhao ZS, Chen CW, Li LH, Foye FA, Sjöström SM, Hua HJ, Aggarwal AR, Alumkal AJ, Beer BT, Gleave GM, Rettig RM, Witte WO, Lara LP, Chinnaiyan CA, Maher MC, Quigley QD, Feng FF. .
      View in: Publisher Site   Mentions:
    50. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106; PMCID: PMC7275746.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    51. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020 04; 157(1):55-61. Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS. PMID: 32139151.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    52. ADRB2 expression in progressive metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):145-145. Kwon KD, Zhang ZL, Foye FA, Chen CW, Feng FF, Bailey BA, Huang HJ, Quigley QD, Stuart SJ, Friedl FV, Weinstein WA, Beer BT, Alumkal AJ, Rettig RM, Gleave GM, Lara LP, Li LP, Lui LA, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    53. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discov. 2020 03; 10(3):351-370. Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. PMID: 32071145.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    54. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clin Cancer Res. 2020 04 15; 26(8):1965-1976. Li Y, Yang R, Henzler CM, Ho Y, Passow C, Auch B, Carreira S, Nava Rodrigues D, Bertan C, Hwang TH, Quigley DA, Dang HX, Morrissey C, Fraser M, Plymate SR, Maher CA, Feng FY, de Bono JS, Dehm SM. PMID: 31932493; PMCID: PMC7165042.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    55. Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting. Prostate. 2020 02; 80(2):113-132. Miyahira AK, Sharp A, Ellis L, Jones J, Kaochar S, Larman HB, Quigley DA, Ye H, Simons JW, Pienta KJ, Soule HR. PMID: 31825540; PMCID: PMC7301761.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    56. Niche-Specific Factors Dynamically Regulate Sebaceous Gland Stem Cells in the Skin. Dev Cell. 2019 11 04; 51(3):326-340.e4. Veniaminova NA, Grachtchouk M, Doane OJ, Peterson JK, Quigley DA, Lull MV, Pyrozhenko DV, Nair RR, Patrick MT, Balmain A, Dlugosz AA, Tsoi LC, Wong SY. PMID: 31564613; PMCID: PMC6832854.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    57. A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS. Elife. 2019 09 03; 8. McMahon M, Contreras A, Holm M, Uechi T, Forester CM, Pang X, Jackson C, Calvert ME, Chen B, Quigley DA, Luk JM, Kelley RK, Gordan JD, Gill RM, Blanchard SC, Ruggero D. PMID: 31478838; PMCID: PMC6776443.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    58. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clin Cancer Res. 2019 09 15; 25(18):5608-5622. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. PMID: 31266829; PMCID: PMC6744969.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    59. Abstract 2291: Single cell capture and molecular analysis of live CTCs using integrated microwells and single cell aspirator. Cancer Research. 2019 Jul 1; 79(13_Supplement):2291-2291. Stahlfeld SC, Tokar TJ, Quigley QD, Niles ND, Sperger SJ, Feng FF, Lang LJ. .
      View in: Publisher Site   Mentions:
    60. Differential cell surface protein expression in response to PARP inhibition in BRCA1 mutant isogenic ovarian and breast cancer cells using a novel proteomic technique. Gynecologic Oncology. 2019 Jun 1; 154:50. Freeman FA, Bakker BS, Weeks WA, Diolaiti DM, Quigley QD, Chapman CJ, Chen CL, Ashworth AA. .
      View in: Publisher Site   Mentions:
    61. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. PMID: 31010837; PMCID: PMC7883384.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    62. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    63. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    64. High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Exp Cell Res. 2019 05 01; 378(1):76-86. Sabelström H, Quigley DA, Fenster T, Foster DJ, Fuchshuber CAM, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ, James CD, Norling B, Berger MS, Persson AI. PMID: 30844389.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    65. Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 2019 Mar 1; 37(7_suppl):146-146. Chen CW, Aggarwal AR, Zhang ZL, Zhao ZS, Beer BT, Quigley QD, Foye FA, Playdle PD, Lloyd LP, Rettig RM, Gleave GM, Evans EC, Lara LP, Kothari KV, Chi CK, Reiter RR, Maher MC, Feng FF, Small SE, Alumkal AJ. .
      View in: Publisher Site   Mentions:
    66. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    67. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 68     Fields:    
    68. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 08; 16(8):933-937. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. PMID: 30099369.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    69. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 295     Fields:    Translation:HumansCells
    70. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Rep. 2018 02 13; 22(7):1875-1888. Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ. PMID: 29444438; PMCID: PMC8556706.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    71. Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. Mol Cancer Res. 2018 05; 16(5):777-790. Ilkhanizadeh S, Sabelström H, Miroshnikova YA, Frantz A, Zhu W, Idilli A, Lakins JN, Schmidt C, Quigley DA, Fenster T, Yuan E, Trzeciak JR, Saxena S, Lindberg OR, Mouw JK, Burdick JA, Magnitsky S, Berger MS, Phillips JJ, Arosio D, Sun D, Weaver VM, Weiss WA, Persson AI. PMID: 29431617; PMCID: PMC5932284.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    72. EXTH-23. ANTISECRETORY FACTOR-MEDIATED LOWERING OF INTERSTITIAL FLUID PRESSURE PRODUCES ANTI-TUMOR ACTIVITY IN GLIOBLASTOMA. Neuro-Oncology. 2017 Nov 6; 19(suppl_6):vi77-vi77. Sabelstrom SH, IIkhanizadeh IS, Miroshnikova MY, Frantz FA, Zhu ZW, Idilli IA, Quigley QD, Fenster FT, Yuan YE, Saxena SS, Mouw MJ, Burdick BJ, Magnitsky MS, Berger BM, Arosio AD, Sun SD, Weaver WV, Weiss WW, Persson PA. .
      View in: Publisher Site   Mentions:
    73. Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Oncoimmunology. 2017; 6(11):e1356142. Quigley DA, Tahiri A, Lüders T, Riis MH, Balmain A, Børresen-Dale AL, Bukholm I, Kristensen V. PMID: 29147603; PMCID: PMC5674948.
      View in: PubMed   Mentions: 24     Fields:    
    74. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426; PMCID: PMC5581695.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    75. Panx3 links body mass index and tumorigenesis in a genetically heterogeneous mouse model of carcinogen-induced cancer. Genome Med. 2016 08 09; 8(1):83. Halliwill KD, Quigley DA, Kang HC, Del Rosario R, Ginzinger D, Balmain A. PMID: 27506198; PMCID: PMC4977876.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    76. Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer. Cell Rep. 2016 07 26; 16(4):1153-1165. Quigley DA, Kandyba E, Huang P, Halliwill KD, Sjölund J, Pelorosso F, Wong CE, Hirst GL, Wu D, Delrosario R, Kumar A, Balmain A. PMID: 27425619; PMCID: PMC5087975.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    77. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Rep. 2016 Mar 15; 14(10):2490-501. Campbell J, Ryan CJ, Brough R, Bajrami I, Pemberton HN, Chong IY, Costa-Cabral S, Frankum J, Gulati A, Holme H, Miller R, Postel-Vinay S, Rafiq R, Wei W, Williamson CT, Quigley DA, Tym J, Al-Lazikani B, Fenton T, Natrajan R, Strauss SJ, Ashworth A, Lord CJ. PMID: 26947069; PMCID: PMC4802229.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    78. Abstract P6-08-05: Protein tyrosine kinase activity and miRNA expression profiling reveals differences according to progesterone-receptor-status in HER-2 negative breast cancer. Poster Session Abstracts. 2016 Feb 15; p6-08-05-p6-08-05. Tahiri TA, Satheesh SS, de Wijn dR, Lders LT, Aure AM, Quigley QD, Bukholm BI, Hurtado HA, Kristensen KV, Geisler GJ. .
      View in: Publisher Site   Mentions:
    79. Abstract B59: Age and estrogen-dependent inflammation in breast adenocarcinoma and normal breast tissue. Tumor Microenvironment and Immunotherapy. 2016 Feb 1; b59-b59. Quigley QD, Tahiri TA, Lüders LT, Riis RM, Balmain BA, Børresen-Dale BA, Bukholm BI, Kristensen KV. .
      View in: Publisher Site   Mentions:
    80. ATPS-63OSMOTIC SWELLING REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 2015 Nov 1; 17(suppl_5):v32-v32. Iikhanizadeh IS, Miroshnikova MY, Frantz FA, Zhu ZW, Idilli IA, Quigley QD, Lakins LJ, Magnitsky MS, Phillips PJ, James JD, Berger BM, Arosio AD, Sun SD, Weaver WV, Weiss WW, Persson PA. .
      View in: Publisher Site   Mentions:
    81. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol. 2015 Dec; 9(10):2054-62. Quigley DA, Kristensen V. PMID: 26607741; PMCID: PMC5528725.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCells
    82. Equalizer reduces SNP bias in Affymetrix microarrays. BMC Bioinformatics. 2015 Jul 30; 16:238. Quigley D. PMID: 26223252; PMCID: PMC4518889.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    83. The genetics of splicing in neuroblastoma. Cancer Discov. 2015 Apr; 5(4):380-95. Chen J, Hackett CS, Zhang S, Song YK, Bell RJ, Molinaro AM, Quigley DA, Balmain A, Song JS, Costello JF, Gustafson WC, Van Dyke T, Kwok PY, Khan J, Weiss WA. PMID: 25637275; PMCID: PMC4390477.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    84. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature. 2015 Jan 22; 517(7535):489-92. Westcott PM, Halliwill KD, To MD, Rashid M, Rust AG, Keane TM, Delrosario R, Jen KY, Gurley KE, Kemp CJ, Fredlund E, Quigley DA, Adams DJ, Balmain A. PMID: 25363767; PMCID: PMC4304785.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansAnimals
    85. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res. 2015 Mar; 13(3):493-501. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin SF, Caldas C, Balmain A, Børresen-Dale AL, Kristensen V. PMID: 25351767; PMCID: PMC4465579.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    86. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep. 2014 Nov 06; 9(3):1034-46. Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan Q, Weiss WA. PMID: 25437558; PMCID: PMC4251494.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    87. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res. 2014 Jul 01; 20(13):3569-80. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, Caldas C, Langerød A. PMID: 24803582.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCells
    88. Identification of Hipk2 as an essential regulator of white fat development. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7373-8. Sjölund J, Pelorosso FG, Quigley DA, DelRosario R, Balmain A. PMID: 24785298; PMCID: PMC4034214.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    89. The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. Mol Oncol. 2014 Mar; 8(2):273-84. Quigley DA, Fiorito E, Nord S, Van Loo P, Alnæs GG, Fleischer T, Tost J, Moen Vollan HK, Tramm T, Overgaard J, Bukholm IR, Hurtado A, Balmain A, Børresen-Dale AL, Kristensen V. PMID: 24388359; PMCID: PMC3964809.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    90. Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. Genes Dev. 2013 Mar 15; 27(6):670-82. Wong CE, Yu JS, Quigley DA, To MD, Jen KY, Huang PY, Del Rosario R, Balmain A. PMID: 23512660; PMCID: PMC3613613.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    91. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013; 4:1701. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. PMID: 23591868; PMCID: PMC4450149.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    92. Abstract P5-05-03: The 5p12 breast cancer susceptibility locus is associated with MRPS30 expression in estrogen receptor - positive tumors. Poster Session Abstracts. 2012 Dec 15; p5-05-03-p5-05-03. Quigley QD, Van Loo VP, Alnæs AG, Tost TJ, Zelenika ZD, Balmain BA, Børresen-Dale BA, Kristensen KV. .
      View in: Publisher Site   Mentions:
    93. Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nat Commun. 2012 Jan 10; 3:616. Benzinou M, Clermont FF, Letteboer TG, Kim JH, Espejel S, Harradine KA, Arbelaez J, Luu MT, Roy R, Quigley D, Higgins MN, Zaid M, Aouizerat BE, van Amstel JK, Giraud S, Dupuis-Girod S, Lesca G, Plauchu H, Hughes CC, Westermann CJ, Akhurst RJ. PMID: 22233626; PMCID: PMC3509798.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    94. Erratum: Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nature Communications. 2012 Jan 1; 3(1):1148. Benzinou BM, Clermont CF, Letteboer LT, Kim KJ, Espejel ES, Harradine HK, Arbelaez AJ, Luu LM, Roy RR, Quigley QD, Higgins HM, Zaid ZM, Aouizerat AB, van Amstel vJ, Giraud GS, Dupuis-Girod DS, Lesca LG, Plauchu PH, Hughes HC, Westermann WC, Akhurst AR. .
      View in: Publisher Site   Mentions:
    95. Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. Mol Cancer Res. 2011 Oct; 9(10):1339-45. To MD, Quigley DA, Mao JH, Del Rosario R, Hsu J, Hodgson G, Jacks T, Balmain A. PMID: 21807965; PMCID: PMC3196775.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    96. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res. 2011 Mar 15; 71(6):2339-49. Connolly EC, Saunier EF, Quigley D, Luu MT, De Sapio A, Hann B, Yingling JM, Akhurst RJ. PMID: 21282335; PMCID: PMC3059399.
      View in: PubMed   Mentions: 43     Fields:    Translation:AnimalsCells
    97. Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility. Genome Biol. 2011; 12(1):R5. Quigley DA, To MD, Kim IJ, Lin KK, Albertson DG, Sjolund J, Pérez-Losada J, Balmain A. PMID: 21244661; PMCID: PMC3091303.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    98. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3770-8. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, Mao JH, Balmain A. PMID: 20625127; PMCID: PMC2917310.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    99. 606 Evolution of genetic and gene expression networks during tumour development. European Journal of Cancer Supplements. 2010 Jun 1; 8(5):155. To TM, Quigley QD, Sjolund SJ, Balmain BA. .
      View in: Publisher Site   Mentions:
    100. Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat Rev Genet. 2009 09; 10(9):651-7. Quigley D, Balmain A. PMID: 19636343.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    101. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature. 2009 Mar 26; 458(7237):505-8. Quigley DA, To MD, Pérez-Losada J, Pelorosso FG, Mao JH, Nagase H, Ginzinger DG, Balmain A. PMID: 19136944; PMCID: PMC4460995.
      View in: PubMed   Mentions: 74     Fields:    Translation:Animals
    102. On the origin of lateral asymmetry. Chromosoma. 1996; 104(5):345-7. Goodwin EH, Meyne J, Bailey SM, Quigley D. PMID: 8575246.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    David's Networks
    Concepts (328)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (81)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.